RT Journal Article
SR Electronic
T1 Peptide receptor radionuclide therapy (PRRT) of midgut neuroendocrine tumors: assessment of quality of life
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1437
OP 1437
VO 57
IS supplement 2
A1 Milka Marinova
A1 Martin Muecke
A1 Felix Fischer
A1 Markus Essler
A1 Henning Cuhls
A1 Lukas Radbruch
A1 Hojjat Ahmadzadehfar
YR 2016
UL http://jnm.snmjournals.org/content/57/supplement_2/1437.abstract
AB 1437Objectives Excellent response to PRRT in midgut neuroendocrine tumors (NET) is known what has been confirmed recently by Netter1 study. The aim of this study was to evaluate changes in quality of life of patients with midgut-NET following PRRT.Methods Seventy patients with Midgut-NET (40 female, aged 64±12.2y) underwent PRRT. At baseline 33 patients presented with ECOG 0, 31 patients with ECOG 1, and 6 patients with ECOG 2. Clinical assessment included evaluation of quality of life and symptom changes using standardized questionnaires (EORTC QLQ-C30) and was performed prior to treatment and at follow-up every three months after each therapy cycle up to one year.Results PRRT was performed at least twice in each patient, and up to four treatment cycles in 15 patients. Compared to baseline status, quality of life was improved revealing increased global health status (3 months after 1st, 2nd and 3rd treatment cycle p=0.05, p=0.004, and p= 0.041, respectively), emotional functioning (3 months after 1st and 2nd p<0.001, after 3rd cycle p=0.001y) and cognitive functioning (3 months after 1st and 2nd cycle p=0.003 and p=0.05, respectively). Furthermore, some symptoms showed a significant alleviation compared to baseline such as pain (six months after 1st treatment cycle p=0.038), diarrhoea (9 and 12 months after 1st cycle p=0.036 and p=0.021, respectively), or financial difficulties (3 months after 1st and 2nd p=0.032 and p=0.046, respectively). In addition, changes of quality of life after PRRT were even more pronounced between ECOG groups.Conclusions PRRNT is an effective treatment of midgut-NET improving quality of life of patients in terms of increasing global health and functional status and alleviating some symptoms.